直接抗乙肝病毒候选药物的临床试验研究进展  

The recent advance of direct anti-HBV drug candidates in clinical trials

作　　者：王美 刘林月 李传举 刘俊 贾海永 WANG Mei;LIU Lin-yue;LI Chuan-ju;LIU Jun;JIA Hai-yong(School of Pharmacy,Weifang Medical University,Weifang 261053,China;School of Nursing,Weifang Medical University,Weifang 261053,China)

机构地区：[1]潍坊医学院药学院,山东潍坊261053 [2]潍坊医学院护理学院,山东潍坊261053

出　　处：《药学学报》2022年第10期2972-2984,共13页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81903468);山东省自然科学基金资助项目(ZR2019BH068);山东省医药卫生科技发展计划项目(2018WS061)。

摘　　要：乙型肝炎病毒感染是一个严重的全球公共卫生问题,慢性乙肝感染能够导致肝硬化、肝代谢失常和肝癌等疾病,严重威胁人类身体健康。已有的用于治疗慢性乙肝的核苷(酸)类和干扰素类药物不能彻底清除共价闭合环状DNA(cccDNA)和整合的HBV基因组DNA,因而无法实现慢性乙肝的功能性治愈。目前,一系列靶向于HBV生命周期的药物和免疫调节剂已进入临床试验阶段。本综述回顾了慢性乙肝的治疗现状,以及直接抗病毒候选药物的最新研究进展。Hepatitis B virus(HBV)infection is a serious global public health problem.Chronic hepatitis B virus infection can cause health problems such as cirrhosis,liver metabolism disorders and hepatocellular carcinoma.Nucloes(t)ide analogues and interferon drugs used to treat chronic HBV infection do not completely eradicate covalently closed circular DNA(cccDNA)and integrated genome of HBV DNA,so that they cannot achieve the functional cure of chronic HBV infection.Currently,a series of drugs targeting the phases of HBV lifecycle and immunomodulators have entered clinical trials.Here,we review the current status of the therapeutic drugs as well as the recent advance of direct antiviral agents.

关 键 词：乙型肝炎病毒 药物作用靶点 核苷(酸)类似物 直接抗病毒药物 

分 类 号：R914[医药卫生—药物化学]